ストックスクリーナーアプリを入手
4.85
16.23%
-0.94
プレマーケット:
4.09
-0.76
-15.67%
Artelo Biosciences Inc (ARTL) 最新ニュース
Algorand Edges Lower: No Catalysts Amid Pharma Noise - Bitget
Artelo Biosciences (ARTL) Explores New Avenues for Muscle Preser - GuruFocus
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments - The Manila Times
GLP-1 weight loss can cut lean mass; Artelo starts protection study - Stock Titan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Artelo Biosciences Expands Clinical Pipeline into Glaucoma Market with Investigator-Sponsored Study - Quiver Quantitative
Artelo Biosciences Expansion into $16.3B Glaucoma Market, - GlobeNewswire
[S-1] ARTELO BIOSCIENCES, INC. F... - Stock Titan
Artelo Biosciences (ARTL) seeks $10.9M in dilutive stock and warrant raise - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Nano-cap Artelo Biosciences stock explodes — glaucoma study collaboration ignites rally - MSN
[S-1/A] ARTELO BIOSCIENCES, INC. Amends IPO Registration Statement - Stock Titan
Why is ARTL stock soaring pre-market today? - MSN
ARTL Stock Price, Quote & Chart | ARTELO BIOSCIENCES INC (NASDAQ:ARTL) - ChartMill
Artelo Biosciences Surges with Groundbreaking Glaucoma Study Announcement - timothysykes.com
Artelo Biosciences (NASDAQ: ARTL) details $10.8M S-1 stock sale - Stock Titan
Artelo Biosciences, Inc.Common Stock (NQ: ARTL - The Chronicle-Journal
Artelo Biosciences Surges on Glaucoma Study Announcement - StocksToTrade
Artelo Biosciences Jumps 28% During the Day Amid Uncertainty Fueling Market Fluctuations and Rumors - Bitget
Artelo Biosciences Surges 28% Intraday as Mystery Drives Volatility and Speculation - Bitget
Artelo Biosciences Expands Market Footprint: Stock Soars Amid Glaucoma Study Initiatives - timothysykes.com
Stay updated with the stocks that are on the move in today's pre-market session. - ChartMill
Small Cap Stocks To Watch Now – March 18th - Defense World
Crude Oil Moves Higher; Jabil Shares Slide After Q2 Results - Sahm
3 Penny Stocks to Watch Now, 3/19/26 - TipRanks
Artelo Biosciences Enters Securities Purchase Agreements for Bridge Notes with Vanquish Funding Group and Boot Capital LLC - Minichart
Artelo Biosciences Secures Bridge Financing Through Note Issuance - TipRanks
Artelo Biosciences Raises $310,000 in 12% Bridge Notes From Vanquish and Boot - TradingView
Artelo Biosciences (NASDAQ: ARTL) raises cash via 12% bridge notes - Stock Titan
Artelo Biosciences, Inc. 2025 Financial Results: Going Concern Risks, Capital Raises, and Significant Losses Detailed in Annual Report - Minichart
Small Cap Stocks To Watch NowMarch 18th - MarketBeat
Why Is Artelo Biosciences Stock Surging Today?Artelo Biosciences (NASDAQ:ARTL) - Benzinga
Artelo Biosciences completes 1-for-3 reverse stock split By Investing.com - Investing.com India
Artelo Biosciences (ARTL) Soars 40% After Securing Fully-Funded Glaucoma Trial Partnership - MEXC
Artelo Biosciences stock surges on glaucoma study agreement By Investing.com - Investing.com South Africa
Artelo Biosciences stock surges on glaucoma study agreement - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Artelo Biosciences moves into glaucoma research with fully funded clinical study - MSN
Artelo Biosciences (ARTL) Stock Jumps 40% on Surprise Glaucoma Study News - MEXC
Artelo announces third-party fully funded clinical study agreement for ART27.13 - TipRanks
Artelo Biosciences’ Stock Increases with Positive R&D Updates - StocksToTrade
Artelo Biosciences jumps as it expands ART27.13 into glaucoma via fully funded clinical study - Quiver Quantitative
Artelo Biosciences (ARTL) Stock Rockets 40% Following Glaucoma Trial Partnership - parameter.io
Artelo Biosciences Shares Surge Amid Promising Research Updates - timothysykes.com
Dow Falls Over 150 POints; US Producer Prices Increase In February - Benzinga
Morning Market Movers: ARTL, SWMR, OVID, HIT See Big Swings - RTTNews
Artelo Biosciences (ARTL) Explores New Glaucoma Treatment in Upc - GuruFocus
Why Is ARTL Stock Soaring Pre-Market Today? - Asianet Newsable
Artelo Biosciences and Belfast Health and Social Care Trust Enter Definitive Investigator-Initiated Study Agreement - marketscreener.com
Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study - marketscreener.com
Clinical Collaboration and Funding Arrangement: Artelo Biosciences, Inc. (NASDAQ: ARTL) announces the signing of a third-party fully funded clinical research agreement to advance the evaluation of its candidate drug ART27.13 in glaucoma patients. - Bitget
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients - GlobeNewswire
1.82%
大文字化:
|
ボリューム (24 時間):